Background {#Sec1}
==========

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome that presents with unremitting fever, splenomegaly and cytopenia \[[@CR1]\]. According to the HLH-2004 protocol, HLH can be defined as fulfillment of at least five of eight clinical and laboratory criteria \[[@CR2]\]. Primary, genetic, as well as secondary forms of HLH have been described. HLH is typically treated by immunosuppression, followed by hematopoietic stem cell transplantation in familial cases \[[@CR1]\]. Current HLH criteria poorly discriminate underlying causes of disease. Importantly, therapies tailored to different etiologies of HLH may improve treatment outcome \[[@CR3]\].

Several genetic disorders predispose to HLH, but vary in their risk of developing disease. Congenital defects affecting the perforin-mediated lymphocyte cytotoxicity, such as autosomal recessive mutations in *PRF1*, *UNC13D*, *STX11*, and *STXBP2*, represent the most common causes of primary HLH, termed familial HLH (FHL) type 2, 3, 4 and 5, respectively \[[@CR1], [@CR4]\]. The impaired killing of infected as well as activated immune cells results in the sustained hyperinflammatory state characteristic of HLH, where animal models have postulated a critical role for CD8^+^ T cells and interferon (IFN)-γ \[[@CR5]\]. Patients with autosomal recessive mutations in *RAB27A* and *LYST*, causative of Griscelli syndrome type 2 (GS2) and Chediak-Higashi syndrome (CHS), respectively, also frequently develop HLH. Besides defective lymphocyte cytotoxicity, these syndromes are associated with hypopigmentation \[[@CR6], [@CR7]\]. Only one case of HLH has been reported in Hermansky-Pudlak syndrome type 2, another hypopigmentation syndrome specifically caused by mutations in *AP3B1* and associated with impaired lymphocyte cytotoxicity \[[@CR8]\]. Moreover, HLH has so far not been reported in Hermansky-Pudlak syndrome type 9 patients, caused by mutations in *BLOC1S6* and also reported to display impaired lymphocyte cytotoxicity \[[@CR9]\]. Genetic disorders displaying a more limited impairment of lymphocyte cytotoxicity may also present with HLH or related lymphoproliferative diseases. Patients with hemizygous mutations in *SH2D1A* or *XIAP*, associated with X-linked lymphoproliferative disease, typically present with HLH or lymphoproliferative diseases, often triggered by Epstein-Barr virus (EBV) infection \[[@CR10]\]. Lymphoproliferation and severe EBV infections are also features of autosomal recessive mutations in *ITK* \[[@CR11]\] and hemizygous mutations in *MAGT1* \[[@CR12]\], with sporadic cases of HLH \[[@CR13], [@CR14]\]. Episodes of HLH have also been reported in patients harboring other primary immunodeficiencies \[[@CR3], [@CR15]--[@CR17]\], providing evidence for hyperinflammatory syndromes fulfilling current HLH criteria in an immunological context of T-cell deficiency or absent IFN-γ signaling. HLH may also arise in the context of inborn errors of metabolism and lysosomal storage disorders, or secondary to infections, malignancies or autoimmune disorders in individuals without any established genetic disease susceptibility \[[@CR1]\].

Patients with defective lymphocyte cytotoxicity usually develop early-onset HLH with high penetrance and require the most radical immunosuppressive therapy. Defective natural killer (NK) cell cytotoxic activity, as measured by the ^51^Cr-release assay, is included among the HLH-2004 diagnostic criteria \[[@CR2]\]. However, pathological results with this assay do not necessarily reflect functional defects in lymphocyte cytotoxicity, but can also be caused by low NK cell numbers. Refined assays have been developed for the identification of patients with defects in lymphocyte cytotoxicity as well as XIAP signaling \[[@CR18]--[@CR20]\]. These assays require considerable technical expertise and rely on fresh blood samples. Therefore, improved diagnostic procedures are required for guidance of treatment decisions.

With current insights, patients with defective lymphocyte cytotoxicity can also be diagnosed by DNA sequencing. To influence the clinical management of HLH patients, genetic diagnostics must be rapid and accurate. Due to genetic heterogeneity, achieving a molecular diagnosis by conventional Sanger sequencing is labor-intensive and time-consuming. Technological advances have increased sequencing throughput, with decreased sequencing times and costs \[[@CR21]\]. As more bench-top sized machines have been pushed to the market, appealing solutions for diagnostic laboratory settings have become available \[[@CR22]\]. Aimed at diagnosing a broad range of immune defects, high-throughput assays have recently been reported for the simultaneous study of a number of primary immunodeficiency syndromes \[[@CR23]--[@CR25]\].

Here, we report our experience in implementing a targeted resequencing approach for identification of HLH patients with defective lymphocyte cytotoxicity. Moreover, we characterize the genetic variants in HLH-related genes in the general population and discuss the implications to interpretation of association of rare, potentially damaging monoallelic variants with disease.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The study was performed using genomic DNA (gDNA) samples from (1) 13 patients with a confirmed molecular diagnosis in an HLH-related gene, (2) 58 patients, prospectively recruited over a 12 months period, fulfilling five or more HLH diagnostic criteria (*n* = 56) or with a cytotoxicity defect suggestive of primary HLH (*n* = 2). Informed consent was obtained from all study participants in accordance with the Declaration of Helsinki. The study was approved by the Regional Ethics Review Board in Stockholm, Sweden.

AmpliSeq custom panel design {#Sec4}
----------------------------

A targeted resequencing panel covering 12 HLH-associated genes was designed according to Ion AmpliSeq technology (Ion Torrent, Thermo Fisher Scientific, MA, USA; Table [1](#Tab1){ref-type="table"}). Using genome build *hg19* as reference, the coding regions, with 25 intronic base pairs around exons, were targeted. For *PRF1*, *UNC13D*, *STX11*, and *STXBP2*, the evolutionarily conserved non-coding regions, identified using the software Alamut (Interactive Bio-software, Rouen, France), were also included. Sequencing data generated by this study has been submitted to the European Genome-phenome Archive and is available from the authors on request.Table 1Genes included in the panelGeneEnsembl gene ID, transcript IDLocusAssociated diseaseNumber of ampliconsCoverage (%)HGMD coverage (%)*PRF1*ENSG00000180644, ENST0000037320910q22.1Familial hemophagocytic lymphohistiocytosis type 211100100*UNC13D*ENSG00000092929, ENST0000020754917q25.1Familial hemophagocytic lymphohistiocytosis type 35198.399.2*STX11*ENSG00000135604, ENST000003675686q24.2Familial hemophagocytic lymphohistiocytosis type 428100100*STXBP2*ENSG00000076944, ENST0000044177919p13.2Familial hemophagocytic lymphohistiocytosis type 52598.5100*SH2D1A*ENSG00000183918, ENST00000371139Xq25X-linked lymphoproliferative disease type 1510098.8*XIAP*ENSG00000101966, ENST00000371199Xq25X-linked lymphoproliferative disease type 21392.292.9*RAB27A*ENSG00000069974, ENST0000039630715q21.3Griscelli syndrome type 210100100*LYST*ENSG00000143669, ENST000003897941q42.3Chediak-Higashi syndrome12097.798.4*AP3B1*ENSG00000132842, ENST000002551945q14.1Hermansky-Pudlak syndrome type 25094100*BLOC1S6*ENSG00000104164, ENST0000022053115q21.1Hermansky-Pudlak syndrome type 9899.1100*MAGT1*ENSG00000102158, ENST00000358075Xq21.1X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia18100100*ITK*ENSG00000113263, ENST000004228435q33.3Inducible T-cell kinase deficiency2296.7100*HGMD* Human Gene Mutation Database

Library preparation and sequencing {#Sec5}
----------------------------------

Library preparation was performed with 10 ng gDNA using Ion AmpliSeq Library Kit 2.0 for each multiplex PCR reaction (Ion Torrent, Thermo Fisher Scientific). The library was thereafter ligated with sequencing adaptors containing barcodes (Ion Xpress Barcode Adapters 1--16 Kit, Ion Torrent, Thermo Fisher Scientific). After purification (Agencourt AMPure XP reagent, Beckman Coulter, Brea, CA, USA), libraries were quantified on an Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA) and diluted to a concentration of 100 pM. Diluted libraries were pooled and further amplified with an emulsion PCR. Enriched templates were loaded onto an Ion 314 or Ion 316 Chip (Ion Torrent, Thermo Fisher Scientific).

Bioinformatics analyses {#Sec6}
-----------------------

Assessment of sequencing quality control, mapping, coverage analysis and variant calling were performed using the Ion Torrent Suite Software (versions 4.0.2 and 4.0.3, Thermo Fisher Scientific). Mapping of sequencing reads to the genome build *hg19* was performed using TMAP software. The Ion Torrent Variant caller (version 4.2.0) was used in "Germline - low stringency" mode with default settings. Integrative Genomics Viewer (IGV) version 2.3.32 \[[@CR26]\] was used for the inspection of sequencing reads and visual assessment of detected variants. Called variants were first annotated with Variant Effector Predictor \[[@CR27]\] followed by GEMINI (version 0.11.0) \[[@CR28]\]. Further analyses were performed with R (version 3.1.2) \[[@CR29]\]. In silico evaluation of candidate variants was performed by reviewing CADD \[[@CR30]\], PolyPhen-2 \[[@CR31]\] and SIFT scores \[[@CR32]\]. NNSPLICE 0.9 was used for predicting the effect of splice-site variants \[[@CR33]\].

Sanger validation and sequencing of poorly covered amplicons {#Sec7}
------------------------------------------------------------

All variants considered pathogenic were validated by Sanger sequencing. Moreover, non-covered or poorly amplified exonic regions were Sanger sequenced in unexplained patients. Primers and PCR conditions are available upon request. The PCR products were purified and sequenced on an ABI 3730 Genetic Analyzer (Applied Biosystems, Thermo Fisher Scientific) and analyzed with SeqScape (version 2.5; Applied Biosystem, Thermo Fisher Scientific). Variant segregation in the family was evaluated depending on availability of parental DNA.

Analysis of mutational load in FHL genes in the 1000 Genomes dataset {#Sec8}
--------------------------------------------------------------------

Variant call format (vcf) files including sequencing data from 2504 individuals from the 1000 Genomes project were analyzed with respect to genes included in the panel (<ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/release/20130502/>, accessed January 2015). Variants were annotated using Variant Effector Predictor \[[@CR27]\] and GEMINI \[[@CR28]\]. All variants deviating from Hardy-Weinberg equilibrium (*p* value \< 0.05) were removed. Further analyses were performed with R (version 3.1.2).

Immunological analyses {#Sec9}
----------------------

Intracellular expression of perforin, granzymes, CD107a, and SAP as well as cytotoxic lymphocyte exocytosis was evaluated by flow cytometry \[[@CR20]\]. NK cell cytotoxicity against K562 target cells was evaluated with a standard 4-hour ^51^Cr-release assay using peripheral blood mononuclear cells (PBMCs) \[[@CR34]\] and the data are shown as lytic units at 25 % specific lysis. All flow cytometry data were acquired on a LSR Fortessa instrument (BD Biosciences, CA, USA). Analyses were performed in Flow Jo v9.7 and R (version 3.1.2).

Results {#Sec10}
=======

Coverage analysis {#Sec11}
-----------------

A custom targeted resequencing panel was designed to cover 12 genes in which mutations have been associated with HLH or lymphoproliferative disorders (Table [1](#Tab1){ref-type="table"}). The panel consisted of 355 primer pairs, with an amplicon size range of 125--175 bp, covering up to 97.3 % of the desired target. Specific primers could not be designed for 1125 bp, due to repetitive regions. Following sequencing, analyses revealed that some amplicons repeatedly failed to generate adequate coverage, as determined by a ≤10× cut-off of mean coverage across samples (Fig. [1a](#Fig1){ref-type="fig"}; Additional file [1](#MOESM1){ref-type="media"}). Excluding two amplicons that failed in nearly all samples (mean coverage ≤10×), the effective coverage of our initial target sequences was estimated to be 96.6 % of the initial regions of interest, with an average coverage per gene over exonic and splice-site regions of 98 % (Table [1](#Tab1){ref-type="table"}). To ensure clinical efficacy, we calculated the proportion of previously reported mutations (based on the Human Gene Mutation database (HGMD), accessed June 2015) with adequate coverage. Overall, 98.6 % of the mutations listed in HGMD were covered by our design (Table [1](#Tab1){ref-type="table"}).Fig. 1Analysis of coverage efficiency and variant filtering strategy. **a** Heatmap indicating coverage for each individual amplicon (355 amplicons) in each patient sample. The coverage is categorized in \<10×, 10--50× or \>50× coverage. Patient samples and amplicon are shown in columns and rows, respectively. Patient samples from both the validation and the prospective cohorts are included. Rows are sorted by position. Columns are sorted by average coverage for each patient. On the right side the bar plot is shown the number of samples with lower coverage (\<10× and 10--50×). The detailed coverage information of all amplicons is reported in Additional file [1](#MOESM1){ref-type="media"}. **b** Flowchart of filtering strategy in the prospective HLH cohort. For each step the bar chart on the right shows the proportions of different types of variants. *MAF* minor allele frequency, *UTR* untranslated region

Assay validation {#Sec12}
----------------

To validate our gene panel, we sequenced gDNA from 13 patients with previously identified genetic defects (Table [2](#Tab2){ref-type="table"}). The patients carried a wide spectrum of mutations located in different genes (Table [2](#Tab2){ref-type="table"}). In order to assess the reliability of the method for detection of homozygous exonic deletions, we also included a patient with a 298-bp homozygous exonic deletion of *STXBP2*. We could identify all 18 small genetic aberrations upon read inspection in IGV. Nonetheless, the variant calling software detected only 17 out of 18 small genetic aberrations (Table [2](#Tab2){ref-type="table"}). The *RAB27A* c.148_149delinsC InDel, located in a homopolymer nucleotide stretch, was instead erroneously called as a synonymous variant (c.148A\>C; Fig. S1a in Additional file [2](#MOESM2){ref-type="media"}). The exonic deletion was easily detected by visual assessment of the coverage over the amplicons (Fig. S1b in Additional file [2](#MOESM2){ref-type="media"}).Table 2Disease-causing mutations used in the validation phaseGeneMutationEffectZygosityTypeCalledReference*PRF1*c.272C\>Tp.Ala91ValHetMissenseYes\[[@CR52]\]*PRF1*c.797T\>Cp.Ile266ThrHetMissenseYesThis study*UNC13D*c.2135_2137delp.Ile712_Gly713delinsSerHetDeletionYesThis study*UNC13D*c.2346_2349delp.Arg782Serfs\*12HetDeletionYes\[[@CR53]\]*UNC13D*c.1388A\>Cp.Gln463ProHetMissenseYes\[[@CR41]\]*UNC13D*c.118-307G\>AReduced expressionHetRegulatoryYes\[[@CR41]\]*UNC13D*C.2719_2722dupp.Ser908TyrfsX3HetDuplicationYesThis study*UNC13D*c.1992+1G\>CAltered splicingHetSplicingYesThis study*STXBP2*exon 2 deletion-HomDeletionYes^a^This study*STXBP2*c.56T\>Cp.Ile19ThrHetMissenseYesThis study*STXBP2*c.704G\>Cp.Arg235ProHetMissenseYesThis study*XIAP*c.877G\>Ap.Gly293SerHemiMissenseYesThis study*XIAP*c.1141C\>Tp.Arg381\*HemiNonsenseYes\[[@CR10]\]*RAB27A*c.148_149delinsCp.Arg50Glnfs\*35HomIndelNo\[[@CR54]\]*RAB27A*c.514_518delp.Gln172Asnfs\*2HomDeletionYes\[[@CR6]\]*LYST*c.2311C\>Tp.Gln771\*HomNonsenseYesthis study*LYST*c.1902dupp.Ala635Serfs\*4HomDuplicationYes\[[@CR55]\]*AP3B1*c.1254dupp.Gln419Thrfs\*22HetDuplicationYesthis study*AP3B1*c.2626C\>Tp.Arg876\*HetNonsenseYesthis study^a^The *STXBP2* exonic deletion was detected by inspection of coverage plots*Hemi* hemizygous, *Het* heterozygous, *Hom* homozygous

We next sought to estimate the overall sensitivity of the variant calling strategy by assessing all exonic polymorphisms (*n* = 56) previously identified in the 13 control samples (Additional file [3](#MOESM3){ref-type="media"}). In total, 74 variants (*n* = 18 mutations and *n* = 56 polymorphisms) were used for the sensitivity analysis. Out of these, 72 variants were properly called. The overall sensitivity was 97.3 % (95 % confidence interval 90.7--99.2, Wilson score method).

Prospective cohort of HLH patients {#Sec13}
----------------------------------

Following validation, we sequenced a cohort of 58 prospectively recruited HLH patients (Fig. [2a](#Fig2){ref-type="fig"}). The median age at diagnosis of HLH was 3 years, ranging from a few days to 70 years (interquartile range = 0.4--13.2 years; Table [3](#Tab3){ref-type="table"}). Eight patients were above 18 years of age at diagnosis of HLH. The included patients were of different ethnic origin, including 43 % from Turkey. Parental consanguinity was reported in 24 cases. Interestingly, six patients also suffered from albinism and eight patients had a familial history of HLH or unexplained siblings' death in childhood (Table [3](#Tab3){ref-type="table"}). Hyperferritinemia, splenomegaly and hypertriglyceridemia and/or hypofibrinogenemia were the most common findings in our cohort. Soluble interleukin-2 receptor (sCD25) was elevated in all seven patients tested (Table [3](#Tab3){ref-type="table"}).Fig. 2Clinical, genetic and functional characteristics of the patients included in the prospective cohort. **a** Heatmap of clinical and functional features of the implementation cohort in relation to HLH-2004 diagnostic criteria \[[@CR2]\]. The patients are ordered based on age at diagnosis of HLH. A family history refers to a positive family history for HLH or unexplained siblings' death in childhood. **b** The different molecular diagnoses achieved in the prospective cohort according to age group at diagnosis of HLH. **c** NK cell cytotoxic activity, displayed as lytic units at 25 % specific lysis, in healthy controls and patients from the implementation cohort grouped in diagnosed (*n* = 10) and undiagnosed (*n* = 13) (significance level \**p* \< 0.05, \*\*\*\**p* \< 0.0001). **d** Intracellular expression of perforin, CD107a, granzyme A and B, and SAP in PBMCs of HLH patients from the implementation cohort. Patients are grouped by their molecular diagnosis (*FHL2*, *n* = 4; *FHL3-4,GS2,CHS*, *n* = 9; *No diagnosis*, *n* = 19). The data are expressed as percentage of normalized median fluorescence intensity (*MFI*) in comparison with healthy controls. Exocytic activity of CD3^−^CD56^+^ NK cells (**e**) and CD8^+^CD57^+^ T cells (**f**) was measured as percentage of CD107a^+^ cells in healthy controls and HLH patients from the implementation cohort. P815 target cells were used alone and in combination with anti-CD16 antibody for NK cells and anti-CD3 antibody for CD8 T cells. Exocytic activity of NK cells was also measured using K562 target cells. Patients are grouped by their molecular diagnosis (*FHL2*, *n* = 4; *FHL3-4,GS2,CHS*, *n* = 9; *No diagnosis*, *n* = 20). The controls used were both local and transport controlsTable 3Clinical characteristics of HLH patients included in the prospective cohortWhole cohort (%)Diagnosed (%)With no diagnosis (%)Number of patients582236Age at diagnosis, years 0--120 of 57 (35)13 of 22 (59)7 of 35 (20) 1--512 of 57 (21)4 of 22 (18)8 of 35 (23) 5--129 of 57 (16)4 of 22 (18)5 of 35 (14) 12--188 of 57 (14)1 of 22 (5)7 of 35 (20) 18+8 of 57 (14)0 of 22 (0)8 of 35 (23)Sex Male28 of 58 (48)10(45)18 (50) Female30 of 58 (52)12(55)18 50)Parental consanguinity24 of 52 (46)14 of 21 (67)10 of 31 (31)Familial history of disease8 of 50 (16)4 of 8 (50)^a^4 of 8 (50)^a^Albinism6 of 43 (14)5 of 6 (83)^a^1 of 6 (17)Fever49 of 54 (91)17 of 20 (85)32 of 34 (94)Splenomegaly55 of 58 (95)21 of 22 (95)34 of 36 (94)Cytopenia (≥2 of 3 lineages)42 of 48 (88)15 of 17 (88)27 of 31 (87) Anemia46 of 54 (85)19 of 21 (90)27 of 33 (82) Thrombocytopenia51 of 57 (89)19 of 21 (90)32 of 36 (89) Neutropenia26 of 50 (52)12 of 16 (75)14 of 34 (41)Hypertriglyceridemia (≥3 mmol/L)38 of 51 (75)13 of 20 (65)25 of 31 (81)Hypofibrinogenemia (≤1 g/L)18 of 50 (36)7 of 18 (39)11 of 32 (34)Hypertriglyceridemia and/or hypofibrinogenemia46 of 50 (92)17 of 19 (89)29 of 31 (94)Hemophagocytosis43 of 49 (88)14 of 17 (82)29 of 32 (91)Hyperferritinemia (≥500 mg/L)54 of 55 (98)19 of 20 (95)35 of 35 (100)Elevated sCD25 (≥2400 U/ml)7 of 7 (100)0 of 07 of 7 (100)^a^Shown as the proportion of patients with documented familial disease and albinism, respectively

Overall, 246 genetic variants were identified in the prospective cohort. Filtering for variants with a possible impact at the protein level, and with a minor allele frequency \<0.05 in the Exome Aggregation Consortium dataset \[[@CR35]\], 71 potentially pathogenic variants were selected for further analysis (Fig. [1b](#Fig1){ref-type="fig"}). After manual curation, 19 variants (single-nucleotide variants or small indels), either in homozygous or compound heterozygous state, were classified as disease-causing (Table [4](#Tab4){ref-type="table"}; Additional file [4](#MOESM4){ref-type="media"}). One additional disease-causing mutation was found upon read inspection in IGV, namely c.148_149delinsC in *RAB27A* (P53). The same disease-causing mutation was also missed by the variant calling program in our validation study (Table [2](#Tab2){ref-type="table"}; Fig. S1a in Additional file [2](#MOESM2){ref-type="media"}).Table 4Details of disease-causing mutations identified in the prospective cohortPatient IDGeneMutationEffectZygosityTypeAssociated diseaseReferenceP48*PRF1*c.272C\>Tp.Ala91ValHetMissenseFHL2\[[@CR52]\]c.1288G\>Tp.Asp430TyrHetMissense\[[@CR56]\]P20*PRF1*c.659G\>Ap.Gly220AspHomMissenseFHL2This studyP35*PRF1*c.673C\>Tp.Arg225TrpHomMissenseFHL2\[[@CR57]\]P16, P40*PRF1*c.1122G\>Ap.Trp374\*HomNonsenseFHL2\[[@CR57]\]P17*PRF1*c.1349C\>Tp.Thr450MetHomMissenseFHL2\[[@CR58]\]P19*PRF1*c.1179C\>Ap.Cys393\*HetNonsenseFHL2This studyc.1434G\>Tp.Leu478ArgHetMissenseThis studyP11*UNC13D*c.569+5G\>AAltered splicing^b^HetSplicingFHL3\[[@CR53]\]inversion^a^HetInversion\[[@CR34]\]P1*UNC13D*c.570-1G\>AAltered splicing^b^HomSplicingFHL3This studyP37*UNC13D*c.753+1G\>TAltered splicing^b^HomSplicingFHL3\[[@CR59]\]P10*UN13D*c.2236C\>Tp.Gln746\*HetNonsenseFHL3This studyc.2346_2349delp.Arg748Serfs\*12HetDeletionP50*UNC13D*c.2709+2T\>AAltered splicing^b^HomSplicingFHL3This studyP58*UNC13D*c.2544delTp.Ile848Metfs\*67HomDeletionFHL3This studyP9, P38, P39*STX11*c.369_376delinsTGGp.Val124Glyfs\*60HomIndelFHL4\[[@CR60]\]P56*STX11*Exonic deletion-HomLarge deletionFHL4NAP26*XIAP*Exonic deletion-HemiLarge deletionXLP2NAP2*LYST*c.9107-20_9109_delAltered splicingHomSplicingCHS\[[@CR61]\]P22*LYST*c.2749_2750delp.Arg917Glyfs\*5HomDeletionCHSThis studyP53*RAB27A*c.148_149delinsCp.Arg50Glnfs\*35HomIndelGS2\[[@CR54]\]P41*RAB27A*c.514_518delp.Gln172Asnfs\*2HomDeletionGS2\[[@CR6]\]^a^ The *UNC13D* inversion was detected with a specific multiplex PCR assay \[[@CR34]\]^b^ As predicted by NNSPLICE 0.9*Hemi* hemizygous, *Het* heterozygous, *Hom* homozygous, *NA* not applicable, *XLP* X-linked lymphoproliferative disease type 2

In addition to analysis of single nucleotide variants and small indels, we performed coverage analysis to identify larger homozygous deletions (Fig. [1a](#Fig1){ref-type="fig"}). We identified a hemizygous deletion of *XIAP* in P26 and a large homozygous deletion of *STX11* in P56 (Fig. S1c, d in Additional file [2](#MOESM2){ref-type="media"}).

Molecular diagnoses {#Sec14}
-------------------

In total, we identified and validated 22 unique disease-causing mutations located in six different genes (Table [4](#Tab4){ref-type="table"}), achieving a molecular diagnosis in 22 patients (overall diagnostic rate 38 %, 22 of 58). The diagnostic yield was higher, 65 % (13 of 20), in the group of patients with HLH presentation before one year of age compared with 24 % (9 of 37) among the older patients (Fig. [2b](#Fig2){ref-type="fig"}). Excluding adult cases of HLH (*n* = 8), the diagnostic rate was 44 % (22 of 50) among the pediatric cases. Interestingly, the oldest patient with primary HLH in this cohort, aged 16 years (P48), had compound heterozygous variants in *PRF1*, c.272C\>T (p.Ala91Val) and c.1288G\>T (p.Asp430Tyr). The variant p.Ala91Val has been associated with later onset of disease when in *trans* to other *PRF1* mutations \[[@CR36]\].

We identified patients with biallelic mutations in *PRF1* (*n* = 7), *UNC13D* (*n* = 6), *STX11* (*n* = 4), *RAB27A* (*n* = 2) and *LYST* (*n* = 2) as well as a patient with a hemizygous mutation in *XIAP* (Fig. [2b](#Fig2){ref-type="fig"}, Table [4](#Tab4){ref-type="table"}). The mutational spectrum was broad, including missense, nonsense, and splicing mutations, indels, small and large deletions. Eight of the 22 identified mutations are novel (Table [4](#Tab4){ref-type="table"}). Mutations were identified in five out of six patients presenting with albinism and HLH. Interestingly, one such patient with albinism (P1) was diagnosed with a homozygous *UNC13D* splice-site mutation (c.570-1G\>A). No patients were found to have mutations in *STXBP2*, *SH2D1A*, *ITK*, *MAGT1*, *AP3B1*, and *BLOC1S6*.

Finally, in 36 out of 58 patients, biallelic variants that could explain the disease phenotype were not detected. The age at diagnosis of HLH was significantly higher compared with genetically diagnosed patients (Wilcoxon rank sum test, *p* = 0.06). Moreover, 61 % (22 of 36) were diagnosed with a concomitant disease known to predispose to secondary HLH. The most commonly associated diseases were EBV infection (*n* = 10), other infections (*n* = 4), and hematological cancer (*n* = 3). In contrast, an infectious trigger was reported in only 4 of 22 (18 %) of the genetically diagnosed patients. Thus, the group of undiagnosed patients had a higher frequency of known triggers of HLH (Fisher's exact test, *p* = 0.002). Of note, seven out of the eight adult HLH cases (88 %) were associated with a known trigger of HLH, suggesting that these may truly represent secondary HLH cases.

Correlation between genetic and functional findings {#Sec15}
---------------------------------------------------

Results from at least one NK cell or CD8^+^ T cell functional assay were available from 33 patients, including 13 patients with a molecular diagnosis and 20 patients without a definitive diagnosis. Substantiating the genetic findings, immunological analyses revealed defective NK cell cytotoxicity and virtually absent perforin expression in the four patients with biallelic *PRF1* mutations studied (Fig. [2a, c, d](#Fig2){ref-type="fig"}). Moreover, CD8^+^ T-cell and NK cell exocytosis was defective in patients with mutations in *UNC13D*, *STX11*, *RAB27A*, and *LYST* (Fig. [2a, e, f](#Fig2){ref-type="fig"}). Interestingly, a patient with *RAB27A* mutations presented with defective NK and CD8^+^ T cell exocytosis, but normal NK cell cytotoxicity, while a patient with *LYST* mutations displayed defective NK cell cytotoxicity but only abnormal NK and CD8^+^ T-cell exocytosis (Fig. [2a, d, e](#Fig2){ref-type="fig"}). Overall, all patients with a genetic diagnosis for which functional data were available displayed a functional defect by at least one diagnostic assay.

Among the undiagnosed patients, seven patients displayed defective NK cell cytotoxicity (\<10 LU; *n* = 6) and/or exocytosis (\<5 % CD107a^+^ NK cells following K562 target cell incubation; *n* = 4). Three such cases belonged to the adult HLH cohort (Fig. [2a](#Fig2){ref-type="fig"}). Therefore, 4 out of 15 pediatric HLH cases (26 %) for which functional data were available displayed a defective NK cell function. In a few cases, the low NK cell cytotoxicity could reflect the low percentage of NK cells in PBMCs (Additional file [5](#MOESM5){ref-type="media"}). Notably, none of the undiagnosed patients with defective exocytosis against K562 target cells displayed concomitant defective NK cell exocytosis following anti-CD16 stimulation or defective CD8^+^CD57^+^ T-cell exocytosis following anti-CD3 stimulation (Fig. [2e](#Fig2){ref-type="fig"}). This result contrasted patients with biallelic *UNC13D*, *STX11*, *STXBP2*, *RAB27A*, or *LYST* mutations, which all displayed defective exocytosis in response to all stimuli. A greater variability has been noted in assays quantifying NK cell exocytosis in response to Fc receptor engagement or CD8^+^CD57^+^ T-cell exocytosis in response to T-cell receptor engagement \[[@CR20]\]. Taken together, it is possible that impaired K562 target cell-induced exocytosis in these patients does not reflect mutations in proteins generally required for cytotoxic lymphocyte exocytosis.

Contribution of monoallelic mutations as cause of HLH {#Sec16}
-----------------------------------------------------

In patients without an established molecular diagnosis based on biallelic or hemizygous mutations, we identified seven different monoallelic variants in nine patients with damaging predictions by either SIFT or PolyPhen-2 (Additional file [6](#MOESM6){ref-type="media"}). These were regarded as monoallelic variants of unknown significance. Three patients carried the variant *PRF1* c.272C\>T p.Ala91Val in a heterozygous state. One of these patients also carried an additional rare variant with pathogenic prediction in *STXBP2* (c.1034C\>T, p.Thr345Met), a combination previously reported in two patients with HLH \[[@CR37]\]. The monoallelic variants were identified among both pediatric (*n* = 7) and adult (*n* = 2) patients. Four out of the nine patients with monoallelic variants were reported to have a known trigger of HLH and only one had a positive family history of unexplained siblings' death in childhood. Overall, 25 % of HLH patients without an established molecular diagnosis carried at least one variant with an in silico damaging prediction.

To interpret findings in patients without an established molecular diagnosis and provide an overview of genetic variations in genes linked to HLH, we examined the frequency of variants in genes included in our panel among 2504 unrelated individuals from the 1000 Genomes project. Discarding intronic variants outside splice-site regions and synonymous variants, 1956 individuals carried at least one variant with a minor allele frequency lower than 0.05. Applying more strict filters (i.e., at least one damaging prediction by either SIFT or PolyPhen-2), 636 individuals (25.4 %) were identified as carrying at least one possibly damaging variant (Additional file [7](#MOESM7){ref-type="media"}). The majority of variants were found in *LYST* and *UNC13D*, likely reflecting gene size (Fig. S3a, b in Additional file [8](#MOESM8){ref-type="media"}). Limiting the analysis to FHL genes, 413 individuals carried at least one possibly damaging variant. Surprisingly, monoallelic variants in genes linked to HLH were thus not enriched in patients with HLH lacking a molecular diagnosis (Fig. S3c, d in Additional file [8](#MOESM8){ref-type="media"}). Nonetheless, the *PRF1* c.272C\>T (p.Ala91Val) variant, in a heterozygous state, showed a weak enrichment (Fisher's exact test, *p* value = 0.07) in patients with HLH but no biallelic mutations. However, a larger cohort of HLH patients lacking biallelic mutations is required to study this association further. Of note, two individuals out of 2504 were homozygous for possibly damaging variants in HLH-related genes, namely *PRF1* c.272C\>T (p.Ala91Val) and *UNC13D* c.1579C\>T (p.Arg527Trp).

Discussion {#Sec17}
==========

Current HLH diagnostic criteria are not specific in discriminating patients with a strong genetic predisposition, typically involving defects in lymphocyte cytotoxicity, from those with a number of other etiologies also associated with HLH \[[@CR1], [@CR3]\]. As treatment recommendations may differ between the groups, molecular studies can have a direct impact on clinical management. Recent technological advances in DNA sequencing have enabled more comprehensive approaches for genetic screening \[[@CR38]--[@CR40]\]. In this study, we developed and validated a targeted high-throughput sequencing approach in order to rapidly identify patients with mutations in genes required for lymphocyte cytotoxicity. Furthermore, we tested the efficacy of our approach on a prospective cohort of 58 patients fulfilling clinical HLH criteria.

Twelve genes, previously linked to HLH, albinism with HLH, or susceptibility to severe EBV infections, were included in our panel. Overall, we achieved 96.6 % coverage of the genes of interest, with an average coverage per gene of 98 %. Moreover, our design covered almost all sites previously reported as mutated. Lack of coverage was mainly due to difficulty of primer design in repetitive regions. Of the designed primer pairs, only a few amplicons failed sequencing. While panels for the simultaneous analysis of several primary immunodeficiency genes have recently been described \[[@CR23]--[@CR25]\], this is the first report of an HLH gene-specific panel implemented on a substantial number of HLH patients. To our knowledge, this also represents the first resequencing panel that targets evolutionarily conserved intronic regions, which is of importance because such regions harbor disease-causing mutations in HLH patients \[[@CR34], [@CR41]\]. The combination of exonic and intronic targets and the spectrum of genes targeted make our panel a comprehensive solution for the molecular diagnostics of HLH patients.

For validation of our variant calling strategy we analyzed 13 patients with a known molecular diagnosis that harbored 18 different mutations and 56 additional variants. The patients were selected in order to cover different kinds of mutations distributed over multiple genes. Our analysis revealed a sensitivity of 97.3 %, comparable to other panels based on Ion Torrent technology \[[@CR24]\]. The only missed disease-causing mutation was located in a homopolymer stretch, regions that are challenging to sequence with Ion Torrent technology \[[@CR42]--[@CR44]\]. All variants were correctly visualized in IGV, suggesting that sensitivity potentially can approximate 100 % through further optimization of variant calling software.

When applied to a heterogeneous cohort of 58 patients, with a clinical diagnosis of HLH (*n* = 56) or with a functional defect suggestive of primary HLH (*n* = 2; defective NK cell activity combined with defective exocytosis or decreased perforin expression), we identified 22 disease-causing mutations, of which eight were novel, in six of the twelve genes included in the panel. In agreement with the results from the validation cohort, the spectrum of mutations identified in the prospective cohort clearly demonstrated that our method identified different kinds of mutations, including a 22-bp homozygous deletion in *LYST*. Notably, three patients were found to carry a homozygous indel (*STX11* c.369_376delinsTGG), which was not detected in another resequencing study \[[@CR23]\]. Moreover, large homozygous deletions were readily identified by coverage analysis and inspection of sequencing reads in both the validation and implementation cohorts. Overall, we achieved a definitive molecular diagnosis in 22 patients (38 %). Biallelic mutations in *PRF1* (*n* = 7) and *UNC13D* (*n* = 6) represented the most common finding.

The diagnostic yield was high in the group of patients diagnosed with HLH before one year of age (65 %). In the largest collection of patients with a suspected diagnosis of HLH studied for mutations in *PRF1*, *UNC13D* and *STXBP2*, biallelic mutations were found in 11 % of all cases, and 24 % of cases with onset of disease before 1 year of age \[[@CR45]\]. The larger proportion of patients with a genetic diagnosis in our cohort may reflect the larger number of genes studied, more specific inclusion criteria, and a high frequency of consanguinity. Rather, our results compare well with data from the Italian HLH registry, where 40 % of HLH patients overall received a definitive molecular diagnosis \[[@CR46]\]. In this cohort, 64 % of HLH patients with an age at onset below 1 year received a molecular diagnosis. Of note, one patient with albinism and HLH was reclassified post-sequencing as FHL3, illustrating a case where phenotypic characteristics potentially could misguide targeted genetic investigations. Conversely, genetic analyses can correct for overlooked phenotypic manifestations \[[@CR47]\]. Moreover, *RAB27A* mutations have recently also been reported in patients without albinism, necessitating *RAB27A* sequencing in all HLH patients with defective exocytosis \[[@CR48]\].

Despite our efforts, 36 patients remained without a definitive molecular diagnosis. Bioinformatics analyses were complemented by visual inspection of sequencing reads and Sanger sequencing of poorly covered amplicons, reducing the likelihood of overlooking mutations. Regulatory mutations or mutations in genes not included in this panel, as well as secondary forms of HLH, are plausible explanations for the lack of genetic findings in these patients. For instance, our small cohort of adult HLH cases may represent secondary HLH. Nonetheless, adult HLH cases should still be studied for primary HLH, as a relatively small proportion of them do harbor biallelic mutations in HLH-related genes \[[@CR45], [@CR46], [@CR49]\]. For three undiagnosed patients with a family history of unexplained siblings' death in childhood, the medical records of the siblings' disease were scarce. Thus, we could not be sure that these represented familial HLH. Conversely, the sister of an additional undiagnosed patient with EBV-driven HLH (P7) also suffered from a prolonged EBV infection with hepatitis, leukopenia, anemia, and prolonged fever at the age of 7 years, suggesting a familial susceptibility to severe EBV infections in this family. Generally, undiagnosed patients had a higher median age at diagnosis and frequency of known triggers for secondary HLH, with the most common trigger being EBV infection. Four undiagnosed pediatric HLH patients displayed defective NK cell cytotoxicity and/or a selective defect in NK cell exocytosis against K562 target cells, possibly suggesting an immune defect more restricted to NK cell function in these patients.

Interestingly, rare monoallelic variants in genes required for lymphocyte cytotoxicity have previously been reported in HLH patients \[[@CR37], [@CR45]\]. However, their contribution to disease development is unclear. We identified nine patients with seven distinct rare monoallelic variants with in silico pathogenic predictions, without any obvious enrichment by age at onset or HLH trigger. Three patients carried the variant *PRF1* p.Ala91Val. To gain understanding of the role of monoallelic variants in HLH, we determined the mutational load of the genes included in our panel among 2504 adults from the 1000 Genomes project \[[@CR50]\]. Remarkably, in comparison to our cohort of undiagnosed patients and even to a larger cohort from the Italian registry with 18 % of monoallelic variants in sporadic HLH \[[@CR46]\], a similar frequency of rare possibly pathogenic variants was found in the 1000 Genomes cohort. Of the 25 rare, possibly pathogenic heterozygous *PRF1* variants identified in the 1000 Genomes project cohort, 11 (36 %) have previously been reported as homozygous or compound heterozygous mutations in patients diagnosed with FHL2. Although rare genetic variants may contribute to disease susceptibility, such conclusions require more rigorous experimental validations as recently exemplified for a dominant-negative *STXBP2* variant \[[@CR51]\]. Although limited in scale and demography, our results suggest a similar burden of heterozygous variants with pathogenic prediction in HLH-associated genes between HLH patients without a known genetic defect and healthy individuals. Thus, prudence is warranted with respect to interpreting causality between rare monoallelic variants and HLH.

Conclusions {#Sec18}
===========

We have demonstrated the efficacy of a high-throughput sequencing approach for the molecular diagnosis of patients with suspected HLH. With more than half of the patients lacking an identified genetic aberration, the genetic susceptibility to HLH remains to be discovered with further genome sequencing and immunological characterization. Moreover, we determined the burden of heterozygous variants with pathogenic prediction of HLH-related genes in the general population and unexpectedly found it similar to that observed in HLH patients without a clear genetic diagnosis. Albeit based on a small cohort, our results imply prudence in ascertaining any causality between monoallelic mutations and HLH. Despite the good accuracy in high-throughput sequencing, such diagnostic approaches are best combined with sensitive functional assays for reliable molecular diagnoses of patients with HLH.
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